Canada markets closed

ORTX May 2022 2.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
As of 11:02AM EST. Market open.
Full screen
Previous Close0.2500
Open0.2500
Bid0.2000
Ask0.3000
Strike2.50
Expire Date2022-05-20
Day's Range0.2500 - 0.2500
Contract RangeN/A
Volume20
Open Interest1.12k
  • GlobeNewswire

    Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome

    100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 2022 following recent meeting to discuss trial design with U.S. and European regulators BOSTON and LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data pu

  • Simply Wall St.

    Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • GlobeNewswire

    Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021

    BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following virtual investor conferences: Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 1:00 p.m. ET. The company is also taking part in a gene therapy development and regulatory panel discussion.Stifel 2021 Virtual Healthcare Conference on Novem